Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Post-traumatic Stress Disorder01:27

Post-traumatic Stress Disorder

491
Post-traumatic stress disorder (PTSD) is a psychiatric condition that arises following exposure to traumatic events such as natural disasters, forced displacement, or severe accidents. It significantly impairs individuals' ability to cope with daily activities and disrupts their emotional and psychological equilibrium.
Symptoms and Behavioral Manifestations
A spectrum of distressing symptoms characterizes PTSD. Recurrent flashbacks, where individuals involuntarily relive traumatic events,...
491
Tissue Transplantation01:24

Tissue Transplantation

936
Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
936
Post-translational Translocation of Proteins to the RER01:27

Post-translational Translocation of Proteins to the RER

7.6K
A sizable fraction of proteins destined for ER are first synthesized in the cell cytosol and then transported across the ER membrane–a process called post-translational translocation. Similar to cotranslationally translocated proteins, these proteins also use the Sec translocon complex to enter the ER lumen.
Targeting proteins to the ER
Hsp40 and Hsp70 chaperone molecules bind the translated proteins in the cytosol to prevent their folding. The chaperone binding helps to keep the signal...
7.6K
Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

351
A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
351
Handwashing III: During the Procedure and Post-Procedure Steps01:15

Handwashing III: During the Procedure and Post-Procedure Steps

2.2K
To wash hands properly, follow these steps:
2.2K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

943
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
943

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Donor Selection and Human Leukocyte Antigen Loss Leukemia Relapse After Hematopoietic Cell Transplantation.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Editorial: NK cells in transplantation.

Frontiers in immunology·2026
Same author

Absolute Risk Trade-offs of Donor Age, Sex, and Graft Source in PTCy-Based Transplantation.

Blood advances·2026
Same author

Hematopoietic Cell Transplant Access and Patient Diversity.

JAMA network open·2026
Same author

Haploidentical versus matched unrelated donor transplantation with post-transplant cyclophosphamide: a platform-dependent machine learning analysis of donor age.

Leukemia·2026
Same author

Challenging a clinical dogma with multimodal machine learning: a retrospective analysis of transplant mismatched donor selection.

Leukemia·2026
Same journal

ALLOPLUS: allogeneic hematopoietic stem cell transplantation in children and adult people living with human immunodeficiency virus, a retrospective study of the SFGM-TC.

Bone marrow transplantation·2026
Same journal

Epigenetic priming with azacitidine-BEAM versus decitabine-BEAM conditioning for autologous transplantation in non-Hodgkin's lymphoma.

Bone marrow transplantation·2026
Same journal

CHIME: a novel HLA eplet model associates with non-relapse mortality in haploidentical hematopoietic cell transplant with post-transplant cyclophosphamide.

Bone marrow transplantation·2026
Same journal

Transplant outcomes for patients with severe acquired aplastic anemia over the age of 40 using busulfan, fludarabine, reduced-dose cyclophosphamide, and anti-thymocyte globulin conditioning regimen.

Bone marrow transplantation·2026
Same journal

A holistic prognostic model for leukemia-free survival after allogeneic transplantation in acute leukemia.

Bone marrow transplantation·2026
Same journal

Early software-assisted response predicts survival in a prospective cohort of 258 newly diagnosed cGvHD patients.

Bone marrow transplantation·2026
See all related articles

Related Experiment Video

Updated: Jan 20, 2026

Generating Chimeric Zebrafish Embryos by Transplantation
21:01

Generating Chimeric Zebrafish Embryos by Transplantation

Published on: July 17, 2009

21.8K

Post-transplantation cyclophosphamide for chimerism-based tolerance.

Shannon R McCurdy1, Leo Luznik2

  • 1Abramson Cancer Center and the Division of Hematology and Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA. shannon.mccurdy@pennmedicine.upenn.edu.

Bone Marrow Transplantation
|August 22, 2019
PubMed
Summary
This summary is machine-generated.

Post-transplant cyclophosphamide (PTCy) effectively induces tolerance in HLA-mismatched related blood or marrow transplantation (haploBMT), reducing graft failure and GVHD. This approach is expanding to non-malignant conditions like sickle cell disease.

More Related Videos

Minimizing Post-Infusion Portal Vein Bleeding during Intrahepatic Islet Transplantation in Mice
06:41

Minimizing Post-Infusion Portal Vein Bleeding during Intrahepatic Islet Transplantation in Mice

Published on: May 10, 2021

4.3K
Murine Full-thickness Skin Transplantation
07:59

Murine Full-thickness Skin Transplantation

Published on: January 2, 2017

21.1K

Related Experiment Videos

Last Updated: Jan 20, 2026

Generating Chimeric Zebrafish Embryos by Transplantation
21:01

Generating Chimeric Zebrafish Embryos by Transplantation

Published on: July 17, 2009

21.8K
Minimizing Post-Infusion Portal Vein Bleeding during Intrahepatic Islet Transplantation in Mice
06:41

Minimizing Post-Infusion Portal Vein Bleeding during Intrahepatic Islet Transplantation in Mice

Published on: May 10, 2021

4.3K
Murine Full-thickness Skin Transplantation
07:59

Murine Full-thickness Skin Transplantation

Published on: January 2, 2017

21.1K

Area of Science:

  • Immunology
  • Transplantation Medicine
  • Hematology

Background:

  • High-dose cyclophosphamide post-transplant (PTCy) is a cornerstone for tolerance induction in HLA-mismatched related haploBMT.
  • PTCy, combined with nonmyeloablative conditioning, demonstrates low rates of graft failure, severe GVHD, and nonrelapse mortality.
  • The established safety profile of PTCy supports its application in non-malignant conditions requiring allogeneic BMT (alloBMT).

Purpose of the Study:

  • To review pre-clinical and clinical evidence supporting PTCy for chimerism-based tolerance induction.
  • To highlight the expansion of PTCy-based haploBMT for non-malignant indications, including sickle cell disease.
  • To explore the potential of PTCy in combined solid organ and alloBMT for tolerance induction, aiming to reduce long-term immunosuppression.

Main Methods:

  • Review of pre-clinical studies on PTCy and hematopoietic chimerism.
  • Analysis of clinical trial data, including a Phase I/II trial and a large BMT CTN study for sickle cell disease.
  • Examination of case reports, series, and small trials of combined solid organ and alloBMT.

Main Results:

  • PTCy enables tolerance in haploBMT, with low rates of graft failure and GVHD.
  • Nonmyeloablative conditioning with PTCy is associated with low nonrelapse mortality.
  • Emerging data support PTCy's efficacy in sickle cell disease and combined organ/BM transplantation.

Conclusions:

  • PTCy is a safe and effective platform for tolerance induction in various alloBMT settings.
  • The application of PTCy is expanding to non-malignant hematologic disorders and combined transplantation strategies.
  • PTCy facilitates donor hematopoietic chimerism, offering a pathway to reduce or eliminate long-term immunosuppression.